SunTrust Banks Inc. restated their neutral rating on shares of Medivation Inc. (NASDAQ:MDVN) in a report issued on Wednesday.

Other analysts also recently issued reports about the company. Canaccord Genuity reaffirmed a buy rating on shares of Medivation in a report on Sunday, July 17th. Citigroup Inc. reaffirmed a buy rating on shares of Medivation in a report on Sunday, June 26th. Wedbush reiterated an outperform rating and set a $66.00 target price (up previously from $63.00) on shares of Medivation in a research report on Tuesday, July 12th. BMO Capital Markets reiterated a market perform rating and set a $50.00 target price on shares of Medivation in a research report on Thursday, July 7th. Finally, Leerink Swann reiterated a market perform rating and set a $64.00 target price on shares of Medivation in a research report on Thursday, July 7th. One equities research analyst has rated the stock with a sell rating, eighteen have issued a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $73.80.

Medivation (NASDAQ:MDVN) opened at 80.87 on Wednesday. The stock’s market cap is $13.42 billion. The firm’s 50-day moving average price is $71.82 and its 200-day moving average price is $58.15. Medivation has a 12 month low of $26.41 and a 12 month high of $81.09.

Medivation (NASDAQ:MDVN) last announced its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.27 by $0.02. The company earned $206 million during the quarter, compared to the consensus estimate of $214.52 million. Medivation had a positive return on equity of 17.57% and a negative net margin of 17.24%. Medivation’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.58 EPS. On average, analysts predict that Medivation will post $1.27 earnings per share for the current year.

Large investors have recently bought and sold shares of the stock. Fuller & Thaler Asset Management Inc. bought a new stake in Medivation during the second quarter worth about $115,000. Advisor Group Inc. acquired a new position in shares of Medivation during the second quarter valued at $121,000. IFP Advisors Inc increased its position in shares of Medivation by 22.1% in the second quarter. IFP Advisors Inc now owns 2,155 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 390 shares during the period. Acrospire Investment Management LLC increased its position in shares of Medivation by 37.5% in the second quarter. Acrospire Investment Management LLC now owns 2,200 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 600 shares during the period. Finally, Mizuho Asset Management Co. Ltd. increased its position in shares of Medivation by 428.8% in the second quarter. Mizuho Asset Management Co. Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 2,067 shares during the period. 87.79% of the stock is currently owned by hedge funds and other institutional investors.

Medivation Company Profile

Medivation, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI).

5 Day Chart for NASDAQ:MDVN

Receive News & Ratings for Medivation Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medivation Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.